Israel Englander Argenx Se Call Options Transaction History

Millennium Management LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$356.95 - $413.29 $52.7 Million - $61 Million	-147,700 Reduced 99.53%	700 $275,000
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $50.3 Million - $75.1 Million	148,400 New	148,400 $56.5 Million
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $16.9 Million - $19.9 Million	49,500 New	49,500 $18.8 Million

383

31.6M

303K

429K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $32.6B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.